Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for

Core Insights - The market anticipates Alvotech (ALVO) will report a year-over-year decline in earnings despite higher revenues for the quarter ending September 2025 [1][3] - The earnings report is scheduled for November 12, and actual results that exceed expectations could lead to a stock price increase, while a miss may result in a decline [2][3] Earnings Estimates - Alvotech is expected to post quarterly earnings of $0.05 per share, reflecting a year-over-year decrease of 73.7% [3] - Revenues are projected to be $128.22 million, which is an increase of 24.5% compared to the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for Alvotech aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the potential deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [9][10] - Alvotech currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12] Historical Performance - In the last reported quarter, Alvotech was expected to post a loss of $0.26 per share but instead reported earnings of $0.14, resulting in a surprise of +153.85% [13] - Over the past four quarters, Alvotech has surpassed consensus EPS estimates three times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Opus Genetics, Inc. is expected to report a loss of $0.14 per share for the same quarter, indicating a year-over-year change of +51.7% [18] - Opus Genetics' revenue is projected to be $2.77 million, down 28.4% from the previous year, with an unchanged consensus EPS estimate leading to an Earnings ESP of 0.00% [19][20]